Literature DB >> 31999546

Chemotherapy intensification for first-line treatment of poor-prognosis metastatic germ cell cancer is not yet ready for prime time.

Di Maria Jiang1, Robert J Hamilton2, Aaron R Hansen.   

Abstract

Entities:  

Year:  2020        PMID： 31999546      PMCID： PMC7012293          DOI： 10.5489/cuaj.6407

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  9 in total

1.  A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).

Authors:  G Daugaard; I Skoneczna; N Aass; R De Wit; M De Santis; H Dumez; S Marreaud; L Collette; J R G Lluch; C Bokemeyer; H J Schmoll
Journal:  Ann Oncol       Date:  2010-11-08       Impact factor: 32.976

2.  Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.

Authors:  Roelof Koster; Alessandra di Pietro; Hetty Timmer-Bosscha; Johan H Gibcus; Anke van den Berg; Albert J Suurmeijer; Rainer Bischoff; Jourik A Gietema; Steven de Jong
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

3.  Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

Authors:  Aditya Bagrodia; Byron H Lee; William Lee; Eugene K Cha; John P Sfakianos; Gopa Iyer; Eugene J Pietzak; Sizhi Paul Gao; Emily C Zabor; Irina Ostrovnaya; Samuel D Kaffenberger; Aijazuddin Syed; Maria E Arcila; Raju S Chaganti; Ritika Kundra; Jana Eng; Joseph Hreiki; Vladimir Vacic; Kanika Arora; Dayna M Oschwald; Michael F Berger; Dean F Bajorin; Manjit S Bains; Nikolaus Schultz; Victor E Reuter; Joel Sheinfeld; George J Bosl; Hikmat A Al-Ahmadie; David B Solit; Darren R Feldman
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

4.  Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.

Authors:  B Köberle; J R Masters; J A Hartley; R D Wood
Journal:  Curr Biol       Date:  1999-03-11       Impact factor: 10.834

5.  Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Authors:  Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo N Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

6.  Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.

Authors:  Darren R Feldman; Gopa Iyer; Lindsay Van Alstine; Sujata Patil; Hikmat Al-Ahmadie; Victor E Reuter; George J Bosl; Raju S Chaganti; David B Solit
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

7.  Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

Authors:  Darren R Feldman; James Hu; Tanya B Dorff; Kristina Lim; Sujata Patil; Kaitlin M Woo; Maryann Carousso; Amanda Hughes; Joel Sheinfeld; Manjit Bains; Siamak Daneshmand; Charlene Ketchens; Dean F Bajorin; George J Bosl; David I Quinn; Robert J Motzer
Journal:  J Clin Oncol       Date:  2016-05-16       Impact factor: 44.544

8.  Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.

Authors:  Jörg T Hartmann; Thomas Gauler; Bernd Metzner; Arthur Gerl; Jochen Casper; Oliver Rick; Marius Horger; Jan Schleicher; Günter Derigs; Regine Mayer-Steinacker; Jörg Beyer; Markus A Kuczyk; Carsten Bokemeyer
Journal:  J Clin Oncol       Date:  2007-12-20       Impact factor: 44.544

9.  Clinical utility of plasma miR-371a-3p in germ cell tumors.

Authors:  Michal Mego; Ton van Agthoven; Paulina Gronesova; Michal Chovanec; Vera Miskovska; Jozef Mardiak; Leendert H J Looijenga
Journal:  J Cell Mol Med       Date:  2018-12-07       Impact factor: 5.310
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.